MedPath

Screening for Early Diagnosis of Nose Cancer

Not Applicable
Recruiting
Conditions
Nasopharyngeal Carcinoma
Registration Number
NCT07019870
Lead Sponsor
National University Hospital, Singapore
Brief Summary

The goal of this clinical trial is to evaluate the effectiveness of screening in identifying nasopharyngeal cancer (NPC), and evaluate the performance of Epstein-Barr virus (EBV) biomarkers in a community screening setting in Singapore.

Participants will assessed for their risk of NPC using EBV Early Antigen (EA) IgA serology and cell-free plasma EBV DNA. If the initial plasma EBV DNA test is positive, a repeat blood sample will be taken and tested. Saliva will also be collected for evaluation of EBV risk strains, but not used for risk evaluation.

1. High risk individuals are determined by:

* a positive EBV EA IgA serology test, and/or

* two consecutive positive plasma EBV DNA tests

High risk individuals will undergo evaluation in the outpatient Otolaryngology clinic. The evaluation includes a head and neck examination, nasoendoscopy and nasopharyngeal biopsy. Clinical data will be collected at yearly intervals, for at least 3 years, with annual clinical examination and blood tests.

2. Low risk individuals are determined by:

* a negative EBV EA IgA serology, and

* a negative plasma EBV DNA test, or an initially positive plasma EBV DNA test followed by a negative plasma EBV DNA test on repeat blood taking.

Low risk individuals will be contacted via phone call every year for at least 3 years to confirm their disease status. Records will also be reviewed at the National Registry of Disease Office, Health Promotion Board, to confirm that the participant has not been diagnosed with nasopharyngeal cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
20000
Inclusion Criteria
  • Chinese, Malay, and mixed ethnicities
  • individuals not diagnosed with NPC
  • individuals with family history of NPC
Exclusion Criteria
  • younger than 35, older than 60
  • individuals already diagnosed with NPC
  • pregnant women

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Stage distribution of NPCFrom enrollment of the participant to follow-up at three years

Stage distribution of NPC diagnosed in study participants, compared to stage distribution of NPC in unscreened individuals routinely diagnosed in the clinic.

Accuracy of EBV IgA serology in identifying NPC casesFrom enrollment of the participant to follow-up at three years

Accuracy of EBV IgA serology including sensitivity, specificity, positive predictive value and negative predictive value

Accuracy of plasma EBV DNA in identifying NPC casesFrom enrollment of the participant to follow-up at three years

Accuracy of plasma EBV DNA including sensitivity, specificity, positive predictive value and negative predictive value

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

National University Hospital

🇸🇬

Singapore, Singapore

National University Polyclinics

🇸🇬

Singapore, Singapore

National University Hospital
🇸🇬Singapore, Singapore
Serene Siow
Contact
(65) 6772 3850
entsch@nus.edu.sg

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.